Brigatinib

Brigatinib
Clinical data
Trade names	Alunbrig, others
Other names	AP26113
AHFS/Drugs.com	Monograph
MedlinePlus	a617016
License data	US DailyMed: Brigatinib;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth
ATC code	L01ED04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name 5-Chloro-2-N-{4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}-4-N-[2-(dimethylphosphoryl)phenyl]pyrimidine-2,4-diamine;
CAS Number	1197953-54-0;
PubChem CID	68165256;
IUPHAR/BPS	7741;
ChemSpider	34982928;
UNII	HYW8DB273J;
KEGG	D10866;
PDB ligand	6GY (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID501027929 ;
Chemical and physical data
Formula	C29H39ClN7O2P
Molar mass	584.10 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1;
	InChI InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34); Key:AILRADAXUVEEIR-UHFFFAOYSA-N;

Brigatinib, sold under the brand name Alunbrig among others, is a small-molecule targeted cancer therapy being developed by Ariad Pharmaceuticals, Inc.^[3] Brigatinib acts as both an anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.^{[medical citation needed]}

Brigatinib could overcome resistance to osimertinib conferred by the EGFR C797S mutation if it is combined with an anti-EGFR antibody such as cetuximab or panitumumab.^[4]

^ "Summary Basis of Decision (SBD) for Alunbrig". Health Canada. 23 October 2014. Retrieved 29 May 2022.
^ "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Retrieved 17 April 2024.
^ Huang WS, Liu S, Zou D, Thomas M, Wang Y, Zhou T, et al. (May 2016). "Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase". Journal of Medicinal Chemistry. 59 (10): 4948–4964. doi:10.1021/acs.jmedchem.6b00306. PMID 27144831.
^ Uchibori K, Inase N, Araki M, Kamada M, Sato S, Okuno Y, et al. (March 2017). "Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer". Nature Communications. 8: 14768. Bibcode:2017NatCo...814768U. doi:10.1038/ncomms14768. PMC 5355811. PMID 28287083.

[1] "Summary Basis of Decision (SBD) for Alunbrig". Health Canada. 23 October 2014. Retrieved 29 May 2022.

[2] "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Retrieved 17 April 2024.

[Huang-3] Huang WS, Liu S, Zou D, Thomas M, Wang Y, Zhou T, et al. (May 2016). "Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase". Journal of Medicinal Chemistry. 59 (10): 4948–4964. doi:10.1021/acs.jmedchem.6b00306. PMID 27144831.

[4] Uchibori K, Inase N, Araki M, Kamada M, Sato S, Okuno Y, et al. (March 2017). "Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer". Nature Communications. 8: 14768. Bibcode:2017NatCo...814768U. doi:10.1038/ncomms14768. PMC 5355811. PMID 28287083.

[1]

[2]

[3]

[4]